Analyst David Risinger of Leerink Partners reiterated a Buy rating on Sanofi (SNYNF – Research Report), reducing the price target to €115.00.
David Risinger has given his Buy rating due to a combination of factors that highlight Sanofi’s strong financial prospects and strategic positioning. One of the key reasons is the attractive valuation of Sanofi’s stock, which is trading at a low price-to-earnings ratio of 10.5 times the estimated adjusted diluted earnings per share for 2026. This suggests that the stock is undervalued relative to its earnings potential.
Additionally, Risinger points to the company’s projected earnings growth, with an expected compound annual growth rate of 8% from 2025 to 2030. This growth is supported by a robust pipeline of products, including significant catalysts expected in the second half of 2025. Furthermore, the strong performance of Dupixent, a key product for Sanofi, continues to drive sales growth across multiple indications. These factors combined reinforce Risinger’s positive outlook and justify the Buy rating despite some adjustments in price targets due to foreign exchange pressures.
In another report released on April 25, UBS also maintained a Buy rating on the stock with a €115.00 price target.
SNYNF’s price has also changed slightly for the past six months – from $107.440 to $102.864, which is a -4.26% drop .